RxDoctor Payments Data

Christopher Schulze, DO

Clinical Cardiac Electrophysiology · Yardley, PANPI 1760572556

Payments from drug & device makers

$57,640in general payments, 2019–2025

Across 88 payments — averaging $655.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$19K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$17K
  • Impulse Dynamics (USA) Inc.$12K
  • Biotronik Inc.$6K
  • Abbott$4K
  • Novo Nordisk$68
  • plus $38 from 2 others

What the payments were for

  • Consulting fees$1,24812%
  • Speaking & faculty fees$6,40061%
  • Food & beverage$2,77227%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,640 in reported general payments places this provider in the 65th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$767,940
Medicare patients
895
Services billed
5,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban522$481,197
XareltoRivaroxaban191$203,102
EntrestoSacubitril/Valsartan133$146,375
JardianceEmpagliflozin53$37,225
Dabigatran EtexilateDabigatran Etexilate Mesylate36$14,267
Amiodarone Hcl237$14,113
FarxigaDapagliflozin Propanediol15$9,508
Repatha SureclickEvolocumab15$8,271
Carvedilol ErCarvedilol Phosphate21$8,216
Rosuvastatin Calcium294$5,853
Dofetilide27$5,650
Flecainide Acetate96$5,407
Valsartan145$5,318
Metoprolol Succinate292$4,587
Amlodipine-AtorvastatinAmlodipine/Atorvastatin16$4,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$14$203,102191 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in Yardley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →